Semax is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Purity assessment relies mainly on reversed-phase high-performance liquid chromatography, which separates the target heptapeptide from truncated sequences, deletion analogues, and oxidised forms. Mass spectrometry, usually coupled to liquid chromatography, confirms identity through the expected molecular ion and reveals modifications such as methionine sulfoxide formation. Amino acid analysis can verify composition, and tandem mass spectrometry supports sequence confirmation. Ultraviolet detection near 254 to 280 nanometres is convenient because the phenylalanine and histidine residues absorb in that region. Nuclear magnetic resonance is rarely used for routine release testing.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
=== As a sawmill === When fastened into a special guide frame, a chainsaw can be used as a portable sawmill to cut bulk wood into planks or boards. Such usage is called a chainsaw mill or Alaskan sawmill.
==== Hurricane Melissa, October 2025 ==== Hurricane Melissa was a Category 5 hurricane which first made landfall at Jamaica on October 28, 2025, and then hit other Caribbean islands. Secretary of State Rubio activated a disaster assistance response team. By October 31, three U.S. CH-47 Chinook helicopters were deployed to Jamaica to help with relief efforts, with five more on the way. In early November, the State Department promised $12 million in aid to Jamaica, $8 million to Haiti, $3 million to Cuba, and $500,000 to The Bahamas.
=== Composition === Vernix has a highly variable makeup but is primarily composed of sebum, cells that have sloughed off the fetus's skin and shed lanugo hair. Chemically, it is water (80%), lipids (10%) and proteins (10%). The lipids include ceramides, cholesterol, fatty acids, triglycerides, waxes and sterol esters, squalene, and phospholipids; multiple detailed analyses of the polar components have been done. The total fatty acid profile in vernix (either as part of lipids or as fatty acids) contains a variety of less common fatty acids, such as omega-7 polyunsaturated fatty acids or non-methylene-interrupted omega-3 fatty acids. The protein composition is relatively understudied. Vernix of term infants has more squalene and a higher wax ester to sterol ester ratio than preterm infants.
Three other studies have attempted to estimate the hidden costs of global agrifood systems. FOLU (2019) estimated them at USD 12 trillion, while Hendricks et al (2023) estimated them at USD 19 trillion. However, the latter, acknowledges the uncertainly in the estimate and concludes that the value would be between USD 7.2 trillion and USD 51.8 trillion. The third estimate in the 2023 edition of the FAO report: The State of Food and Agriculture estimates global hidden costs from agrifood systems to be USD 12.7 trillion. This study also acknowledges the uncertainty in the estimate. The FAO report shows the global value of the hidden costs has a 95 percent chance of being at least USD 10.8 trillion and a 5 percent chance of being at least USD 16 trillion. Differently from the other two studies, the FAO report assesses hidden costs of agrifood systems at the national level for 154 countries. It states these national numbers are consistent and comparable covering the major dimensions (i.e. environmental, health and social) of agrifood system hidden costs, allowing not only comparison across countries, but also across the different dimensions. Following up on the 2023 edition of the FAO report – The State of Food and Agriculture – the subsequent edition provides a detailed breakdown of the hidden costs associated with unhealthy dietary patterns that lead to non-communicable diseases for 156 countries. The report finds that in 2020, global health hidden costs amounted 8.1 trillion 2020 PPP dollars, 70 percent of all of the hidden costs of agrifood systems.
=== Directed cells fusion (syncytium formation) === One recognized feature of the Sendai virus, shared with members of its genus, is the ability to induce syncytia formation in vivo and in vitro in eukaryotic cell cultures. The formation of syncytium helps the virus to avoid neutralizing antibodies of the host organism during the spread of infection. The mechanism for this process is fairly well understood and is very similar to the fusion process employed by the virion to facilitate cellular entry. The activities of the receptor binding hemagglutinin-neuraminidase protein is solely responsible for inducing close interaction between the virus envelope and the cellular membrane. However, it is the F protein (one of many membrane fusion proteins) that, when triggered by local dehydration and a conformational change in the bound HN protein, actively inserts into the cellular membrane, which causes the envelope and the membrane to merge, followed shortly by virion entry. When the HN and F protein are manufactured by the cell and expressed on the surface, the same process may occur between adjacent cells, causing extensive membrane fusion and resulting in the formation of a syncytium. Using the model of cellular hepatocarcinoma (Hep G2), it has been shown that Sendai virus recruits the cellular protein villin for cell fusion and syncytia formation. The villin-actin interaction regulates the fusion of the viral envelope and the cell membrane. Thus, villin is a host cell cofactor that regulates the fusion process.
Sources: en.wikipedia.org
== Causes == Postinflammatory hyperpigmentation develops after the original symptoms of an inflammatory skin condition disappear. Common triggers include acne lesions, cuts, burns, or skin conditions like eczema. Additionally, UV sun exposure and sunburn are involved in the development, darkening, and expansion of hyperpigmented skin lesions. Some medical procedures performed on the skin can cause an inflammatory reaction, which may lead to hyperpigmentation, even if the inflammation itself is temporary. The exact pathogenesis of PIH is poorly understood. It is known to be driven by cytokine-mediated paracrine interactions between keratinocytes and melanocytes, eventually stimulating the melanocytes to dramatically increase production of melanin, which then deposits in the skin.
== Industrial collaborations == Brenner is a former member of the Scientific Advisory Board of Sirtris Pharmaceuticals. He currently serves as chief scientific advisor of Niagen Bioscience and NADMED.
==== Acupuncture and other interventions ==== While acupuncture leads to improvements in pain relief, this improvement is small and may be of questionable importance. Waiting list–controlled trials for peripheral joint osteoarthritis do show clinically relevant benefits, but these may be due to placebo effects. Acupuncture does not seem to produce long-term benefits. Electrostimulation techniques such as TENS have been used to treat osteoarthritis in the knee. However, there is no conclusive evidence to show that it reduces pain or disability. A Cochrane review of low-level laser therapy found unclear evidence of benefit, whereas another review found short-term pain relief for osteoarthritic knees. Further research is needed to determine if balneotherapy for osteoarthritis (mineral baths or spa treatments) improves a person's quality of life or ability to function. There is low-quality evidence that therapeutic ultrasound may be beneficial for people with osteoarthritis of the knee; however, further research is needed to confirm and determine the degree and significance of this potential benefit. Therapeutic ultrasound is safe and reduces pain and improves physical function in knee osteoarthritis. While phonophoresis does not improve functions, it may offer greater pain relief than standard non-drug ultrasound. There is weak evidence suggesting that electromagnetic field treatment may result in moderate pain relief; however, further research is necessary, and it is not known if electromagnetic field treatment can improve quality of life or function.
Hawaiian–Emperor seamount chain (Hawaii hotspot) Louisville Ridge (Louisville hotspot) Walvis Ridge (Gough and Tristan hotspot) Kodiak–Bowie Seamount chain (Bowie hotspot) Cobb–Eickelberg Seamount chain (Cobb hotspot) New England Seamounts (New England hotspot) Anahim Volcanic Belt (Anahim hotspot) Mackenzie dike swarm (Mackenzie hotspot) Great Meteor hotspot track (New England hotspot) St. Helena Seamount Chain–Cameroon Volcanic Line (Saint Helena hotspot) Southern Mascarene Plateau–Chagos-Maldives-Laccadive Ridge (Réunion hotspot) Ninety East Ridge (Kerguelen hotspot) Tuamotu–Line Island chain (Easter hotspot) Austral–Gilbert–Marshall chain (Macdonald hotspot) Juan Fernández Ridge (Juan Fernández hotspot) Tasmantid Seamount Chain (Tasmantid hotspot) Canary Islands (Canary hotspot) Cape Verde (Cape Verde hotspot)
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.